

## Nitrocapsanthin and Nitrofucoxanthin, Respective Products of Capsanthin and Fucoxanthin Reaction with Peroxynitrite

Makoto Tsuboi,<sup>†</sup> Hideo Etoh,<sup>†,‡</sup> Kyuki Kato,<sup>‡</sup> Hiroki Nakatugawa,<sup>‡</sup> Hideki Kato,<sup>‡</sup> Yasunori Maejima,<sup>†</sup> Gaku Matsumoto,<sup>§</sup> Hironobu Mori,<sup>§</sup> Masashi Hosokawa,<sup>||</sup> Kazuo Miyashita,<sup>||</sup> Harukuni Tokuda,<sup>⊥</sup> Nobukuni Suzuki,<sup>⊥</sup> and Takashi Maoka<sup>\*,#</sup>

<sup>†</sup>Graduate of Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

<sup>‡</sup>Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

<sup>§</sup>Research Institute, Kagome Co. Ltd., 17 Nishitomiya, Nasushiobara-shi, Tochigi 329-2762, Japan

<sup>||</sup>Faculty of Fisheries Science, Hokkaido University, 3-1-1 Minato Hakodate, Hokkaido 041-8611, Japan

<sup>⊥</sup>Department of Complementary and Alternative Medicine, Clinical R&D, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8640, Japan

<sup>\*</sup>Research Institute for Production and Development, Shimogamo-morimotocho, Sakyo-ku, Kyoto 606-0805, Japan

**ABSTRACT:** The *in vitro* reactivity of capsanthin (1) and fucoxanthin (2) with peroxynitrite was investigated, and the reaction products produced by scavenging with peroxynitrite were analyzed. (14'*Z*)-Nitrocapsanthin (3) and 12-nitrocapsanthin (4) were isolated from the products of the reaction of capsanthin with peroxynitrite. Similarly, (14*Z*)-15-nitrofucoxanthin (5), (11*Z*)-11-nitrofucoxanthin (6), and (14*Z*,9'*Z*)-15-nitrofucoxanthin (7) were obtained from the reaction of peroxynitrite reaction with fucoxanthin. Capsanthin and fucoxanthin inhibited the nitration of tyrosine by peroxynitrite. Furthermore, nitrocapsanthins (3 and 4) and nitrofucoxanthins (5 and 6) exhibited an inhibitory effect on Epstein–Barr virus early antigen activation in Raji cells and an antiproliferative effect on human pancreatic carcinoma. Moreover, nitrocapsanthins (3 and 4) inhibited carcinogenesis of mouse skin tumors initiated by 7,12-dimethylbenz[*a*]anthracene (DMBN).

**KEYWORDS:** Capsanthin, fucoxanthin, nitrocapsanthin, nitrofucoxanthin, reaction with peroxynitrite

### INTRODUCTION

Carotenoids show an excellent capacity to quench singlet oxygen (<sup>1</sup>O<sub>2</sub>) and inhibit lipid peroxidation. However, they cannot scavenge superoxide anion radicals (O<sub>2</sub><sup>•−</sup>), hydroxy radicals (OH<sup>•</sup>), or hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). On the other hand, there have been few reports on scavenging and/or the reaction of reactive nitrogen species with carotenoids.<sup>1</sup> Peroxynitrite (ONOO<sup>−</sup>), which is one of the reactive nitrogen species, is formed from superoxide (O<sub>2</sub><sup>•−</sup>) and nitric oxide (NO<sup>•</sup>) *in vivo* and is a highly reactive oxidant that causes nitration of the aromatic ring of free tyrosine and protein tyrosine residues. Furthermore, peroxynitrite was found to induce various forms of oxidative damage such as low-density lipoprotein (LDL) oxidation, lipid peroxidation, and DNA strand breakage.<sup>2</sup>

It has been reported<sup>3</sup> that β-carotene is an effective scavenger of nitrogen dioxide (NO<sub>2</sub>), peroxynitrous acid (ONOOH), and peroxynitrite and that the nitrogen atoms derived from nitrogen dioxide were tightly bound to the β-carotene molecule.<sup>3</sup> This suggested that carotenoids scavenge reactive nitrogen species. Thus, we have studied the reaction of carotenoids such as β-carotene, astaxanthin, and lutein with peroxynitrite<sup>4–6</sup> to clarify the mechanism whereby reactive nitrogen species are scavenged by carotenoids and reported the formation of nitro-carotenoids by this reaction.

Capsanthin (1), a major carotenoid in red paprika, has excellent antioxidative<sup>7–9</sup> and anticancer activities.<sup>10–12</sup> Fucoxanthin (2), a major carotenoid in brown algae, has also been

noted to exhibit biological activities such as radical scavenging and singlet oxygen quenching<sup>13</sup> and anticarcinogenic,<sup>14,15</sup> antidiabetic,<sup>16</sup> and antiobesity<sup>17</sup> potential. In this study, we investigated the products of the reaction of capsanthin (1) and fucoxanthin (2) with peroxynitrite (Figure 1). Furthermore, the inhibitory effect of the nitration of tyrosine with capsanthin and fucoxanthin and the antitumor-promoting activity of nitrocapsanthins and nitrofucoxanthins were studied.

### MATERIALS AND METHODS

**General Experimental Procedures.** UV–visible (UV/vis) spectra were recorded with a Hitachi U-2001 in diethyl ether (Et<sub>2</sub>O). Positive ion fast atom bombardment–mass spectrometry (FAB-MS) spectra were recorded using a JEOL JMS-700 110A mass spectrometer with *m*-nitrobenzyl alcohol as a matrix. The <sup>1</sup>H NMR (500 MHz) and <sup>13</sup>C NMR (125 MHz) spectra were measured with a Varian UNITY INOVA 500 spectrometer in CDCl<sub>3</sub> with TMS as an internal standard. High-performance liquid chromatography (HPLC) was performed on a Shimadzu LC-6AD with a Shimadzu SPD-6AV spectrophotometer.


**Reagents.** Capsanthin (1) and fucoxanthin (2) were prepared from paprika and brown algae, respectively, according to the method described previously.<sup>9,11,13</sup> Peroxynitrite, 12-*O*-tetradecanoylphorbol-13-acetate

**Received:** June 8, 2011

**Accepted:** September 7, 2011

**Revised:** September 6, 2011

**Published:** September 07, 2011



**Figure 1.** Structures of carotenoids.

(TPA), 7,12-dimethylbenz[a]anthracene (DMBA), and L-tyrosine were purchased from Sigma Chemical Co. (St. Louis, MO).

**Reaction of Capsanthin and Fucoxanthin with Peroxynitrite.** According to the previous methods,<sup>4–6</sup> capsanthin or fucoxanthin (400 mg) was dissolved in 50 mL of tetrahydrofuran (THF). To this, trifluoroacetic acid (TFA) was added to make up the final concentration to 0.2%, before the addition of 16 mL of peroxynitrite in NaOH solution (final concentration, 6.8 mM). Then, the solution was allowed to react for 1 min. To the above mixture, 300 mL of  $\text{CHCl}_3$  and 300 mL of  $\text{H}_2\text{O}$  were added so as to separate the reaction products into organic and aqueous phases. The whole procedure was performed three times. The organic layer was dried

over anhydrous sodium sulfate and concentrated. This organic concentrate was then subjected to HPLC. For HPLC separation, a 250 mm  $\times$  4.6 mm i.d., 5  $\mu\text{m}$ , Develosil C30-UG-5 column (Nomura Chemical Co., Ltd., Seto, Japan) was used and kept at 40 °C. The mobile phase used was a MeCN/ $\text{H}_2\text{O}$  (82:18 v/v), at a flow rate of 1 mL/min. A more specific separation procedure was performed using a 250 mm  $\times$  4.6 mm i.d., 5  $\mu\text{m}$ , TSK gel ODS 100Z column (Tosoh Corp., Tokyo, Japan), kept at 40 °C with a mobile phase of MeCN/ $\text{H}_2\text{O}$  (75:25 v/v), at a flow rate of 1 mL/min.

(14'Z)-15'-Nitrocapsanthin (**3**). UV/vis  $\lambda_{\text{max}}$  ( $\text{Et}_2\text{O}$ ) nm 359, 456. HR FAB MS  $m/z$  630.4159 [ $\text{M} + \text{H}^+$ ] (calcd for  $\text{C}_{40}\text{H}_{56}\text{O}_5\text{N}$ , 630.4161).  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR (Table 1).

**Table 1.**  $^1\text{H}$  (500 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for (14'*Z*)-15'-Nitrocapsanthin (3) and 12-Nitrocapsanthin (4) and  $^1\text{H}$  (500 MHz) Data for (14*Z*)-15-Nitrofucoxanthin (5), (11*Z*)-11-Nitrofucoxanthin (6), and (14*Z*,9'*Z*)-15-Nitrofucoxanthin (7) in  $\text{CDCl}_3^a$

no.	3			4			5			6			7	
	$\delta^{13}\text{C}$	$\delta^1\text{H}$	mult (J in Hz)	$\delta^{13}\text{C}$	$\delta^1\text{H}$	mult (J in Hz)	$\delta^{13}\text{C}$	$\delta^1\text{H}$	mult (J in Hz)	$\delta^{13}\text{C}$	$\delta^1\text{H}$	mult (J in Hz)	$\delta^1\text{H}$	mult (J in Hz)
1	37.1			37.1			35.8			35.8				
2	48.3	$\alpha$ 1.77 $\beta$ 1.48	overlapped dd (12, 12)	48.3	$\alpha$ 1.77 $\beta$ 1.48	overlapped dd (12, 12)	47.1	$\alpha$ 1.50 $\beta$ ~1.36	overlapped overlapped	47.2	$\alpha$ 1.50 $\beta$ ~1.36	overlapped overlapped	$\alpha$ 1.50 $\beta$ ~1.36	overlapped overlapped
3	64.9	4.00	m	64.8	4.00	m	64.2	3.82	m	64.1	3.82	m	3.82	m
4	42.5	$\alpha$ 2.39 $\beta$ 2.06	dd (17, 6) dd (17, 9)	42.6	$\alpha$ 2.39 $\beta$ 2.04	dd (17, 6) dd (17, 9)	41.6	$\alpha$ 2.35 $\beta$ 1.79	dd (15, 6) dd (15, 9)	41.5	$\alpha$ 2.35 $\beta$ 1.79	dd (15, 6) dd (15, 9)	$\alpha$ 2.35 $\beta$ 1.79	dd (15, 6) dd (15, 9)
5	126.9			127.4			66.1			66.1				
6	137.5			137.6			66.9			66.7				
7	126.9	6.13	d (16)	132.3	6.46	d (15)	41.0	2.61 3.67	d (18) d (18)	41.4	2.67 3.73	d (18) d (18)	2.61 3.67	d (18) d (18)
8	128.1	6.24	d (16)	137.7	6.20	d (15)	198.1			197.8				
9	139.2			148.6			137.2			143.1				
10	130.9	6.16	d (10)	124.0	6.15	d (11)	127.7	7.16	d (11)	128.3	7.31	s	7.16	d (11)
11	130.7	6.95	dd (15, 11)	129.4	7.99	d (11)	126.4	6.74	dd (15, 11)	141.6			6.74	dd (15, 11)
12	136.0	6.41	d (15)	152.4			144.7	6.82	d (15)	141.8	7.91	s	6.82	d (15)
13	149.9			128.4			141.6			129.7				
14	125.4	5.96	d (12)	136.0	6.25	d (11)	123.0	6.49	s	146.1	6.80	d (11)	6.49	s
15	130.3	8.09	d (12)	132.0	6.65	m	150.3			127.5	6.57	dd (14, 11)		
16	28.7	1.07	s	28.8	1.08	s	25.0	0.97	s	24.9	0.98	s	0.97	s
17	30.2	1.07	s	30.2	1.08	s	28.1	1.05	s	28.1	1.05	s	1.05	s
18	21.6	1.73	s	21.7	1.74	s	21.1	1.22	s	21.1	1.22	s	1.23	s
19	13.7	2.02	s	13.5	2.13	s	12.0	1.97	s	13.9	1.72	s	1.96	s
20	14.1	2.18	s	16.4	2.00	s	15.2	1.80	s	14.8	1.86	s	1.80	s
1'	44.0			44.0			35.1			35.1				
2'	50.8	$\alpha$ 2.00 $\beta$ 1.71	overlapped overlapped	50.8	$\alpha$ 2.00 $\beta$ 1.71	m m	45.3	$\alpha$ 2.00 $\beta$ 1.41	overlapped dd (15, 15)	45.4	$\alpha$ 2.00 $\beta$ 1.41	overlapped dd (15, 15)	$\alpha$ 1.99 $\beta$ 1.40	overlapped overlapped
3'	70.3	4.52	m	70.3	4.51	m	67.8	5.38	m	67.9	5.38	m	5.38	m
4'	45.2	$\alpha$ 2.96 $\beta$ 1.49	dd (15, 8) overlapped	45.3	$\alpha$ 2.96 $\beta$ 1.49	m overlapped	45.2	$\alpha$ 2.29 $\beta$ 1.51	dd (15, 6) overlapped	45.2	$\alpha$ 2.29 $\beta$ 1.51	dd (15, 6) overlapped	$\alpha$ 2.29 $\beta$ 1.51	dd (15, 6) overlapped
5'	59.0			59.0			72.6			72.7				
6'	203.0			202.9			117.8			117.6				
7'	122.0	6.51	d (15)	121.3	6.47	d (15)	203.0			202.6				
8'	146.4	7.33	d (15)	146.7	7.33	d (15)	103.2	6.05	s	103.3	6.06	s	6.59	s
9'	140.1			134.4			134.1			134.1				
10'	130.9	6.57	d (11)	140.2	6.53	d (11)	127.7	6.13	d (11)	128.7	6.14	d (11)	6.01	d (11)
11'	138.0	6.75	dd (15, 11)	125.0	6.67	dd (15, 11)	130.8	6.88	dd (15, 11)	127.0	6.69	dd (15, 11)	7.00	dd (15, 11)
12'	139.8	6.65	d (15)	141.4	6.55	d (15)	136.8	6.38	d (15)	136.5	6.36	d (15)	6.33	d (15)
13'	142.1			137.2			135.7			140.9				
14'	121.4	6.41	s	133.9	6.36	d (11)	125.1	5.93	d (12)	131.4	6.28	d (11)	5.93	d (12)
15'	145.1			129.8	6.67	m	131.2	8.12	d (12)	137.4	6.92	dd (14, 11)	8.12	d (12)
16'	25.1	1.38	s	25.8	1.37	s	29.2	1.39	s	29.2	1.39	s	1.37	s
17'	25.8	1.22	s	25.1	1.21	s	32.0	1.07	s	32.0	1.07	s	1.09	s
18'	21.2	0.85	s	21.2	0.85	s	31.2	1.35	s	31.2	1.35	s	1.40	s
19'	13.0	1.98	s	12.9	1.97	s	11.7	1.86	s	14.1	1.83	s	1.84	s
20'	15.2	1.77	s	12.8	1.98	s	14.2	2.18	s	13.1	2.02	s	2.18	s
CH <sub>3</sub> -							21.4	2.04	s	21.4	2.05	s	2.04	s
CO							170.4			170.4				

<sup>a</sup> s, singlet; d, doublet; m, multiplet.

**12-Nitrocapsanthin (4).** UV/vis  $\lambda$  max (Et<sub>2</sub>O) nm 346, 456. HR FAB MS  $m/z$  630.4168 [M + H]<sup>+</sup> (calcd for C<sub>40</sub>H<sub>56</sub>O<sub>5</sub>N, 630.4161). <sup>1</sup>H NMR and <sup>13</sup>C NMR (Table 1).

**(14Z)-15-Nitrofucoxanthin (5).** UV/vis  $\lambda$  max (Et<sub>2</sub>O) nm 314, 451. HR FAB MS  $m/z$  704.4169 [M + H]<sup>+</sup> (calcd for C<sub>42</sub>H<sub>58</sub>O<sub>8</sub>N, 704.4171). <sup>1</sup>H NMR and <sup>13</sup>C NMR (Table 1).

**(11Z)-11-Nitrofucoxanthin (6).** UV/vis  $\lambda$  max (Et<sub>2</sub>O) nm 334, 456. HR FAB MS  $m/z$  704.4168 [M + H]<sup>+</sup> (calcd for C<sub>42</sub>H<sub>58</sub>O<sub>8</sub>N, 704.4171). <sup>1</sup>H NMR and <sup>13</sup>C NMR (Table 1).


**(14Z,9Z)-15-Nitrofucoxanthin (7).** UV/vis  $\lambda$  max (Et<sub>2</sub>O) nm 334, 453. HR FAB MS  $m/z$  704.4167 [M + H]<sup>+</sup> (calcd for C<sub>42</sub>H<sub>58</sub>O<sub>8</sub>N, 704.4171). <sup>1</sup>H NMR (Table 1).

**Inhibition of Nitration of Tyrosine with Peroxynitrite by Carotenoids.** Capsanthin or fucoxanthin (0.2 mg) was dissolved in 1 mL of methanol (MeOH). L-Tyrosine (0.36 mg) was added to this solution. In the control group, L-tyrosine (0.36 mg) was dissolved in 1 mL of MeOH. Then, 20  $\mu$ L of peroxynitrite (final concentration, 6.8 mM) was added to the solution. The same procedure was carried out for  $\gamma$ -tocopherol (0.15 mg), which was used as a positive control for this assay. The solution was subsequently allowed to react for 5 min at room temperature. After that time, the content of nitrotyrosine, a product of the reaction between tyrosine and peroxynitrite, was quantified using HPLC. The following HPLC systems were employed for the quantification of nitrotyrosine. Column: Develosil ODS-UG-5 (20.0 mm  $\times$  250 i.d. mm; mobile phase, phosphate buffer (50 mM)/MeOH (97:3 v/v); flow rate, 1 mL/min; column temp, 40  $^{\circ}$ C; detection, 250 nm. Inhibition of the nitrotyrosine generated was measured by comparing absorbance of the sample solution (in MeOH) and ascorbic acid solution (in H<sub>2</sub>O).

**In Vitro Antitumor-Promoting Activity.** *In Vitro Epstein–Barr Virus (EVA) Early Antigen Activation Induction Effect.* EBV genome-carrying lymphoblastoid cells (Raji cells) derived from Burkitt's lymphoma were cultivated in RPMI-1640 medium with 10% fetal bovine serum (FBS). The Raji cells were incubated for 48 h at 37  $^{\circ}$ C in a medium containing *n*-butyric acid (4 nmol), TPA (32 pmol), and various amounts of test compounds. Smears were made from the cell suspension, and we employed an indirect immunofluorescence technique. Details of the *in vitro* assay on EBV-EA induction have been reported previously.<sup>11,18</sup>

**Antiproliferative Effects of Human Pancreatic Carcinoma (MIA PaCa-2).** The MIA PaCa-2 (PaCa) cell line was established in 1975 from pancreatic tumor tissue of a 65 year old Caucasian male obtained from DS Pharma Biochemical Co. (Osaka, Japan). The cells were cultured in suspension at 37  $^{\circ}$ C in DMEM medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO<sub>2</sub> in air. Nunclon 3.5 cm cell culture dishes from Nunc Co. (Kamstrupvej, Denmark) were used. PaCa cancer cells in the exponential growth phase were seeded and incubated with different concentrations of the carotenoids. For antiproliferation evaluation, the PaCa cells were incubated with the various concentrations of the test substances, and the effect on the cells was assessed after 3 days. For determination of the antiproliferation effects on surviving cells, the cell counting method was used. At the end of each experiment, the visible round-form cells were counted within a fixed range by macroscopic observation. All results are expressed as the number of round-form cells as a percentage of all visible cells.<sup>19</sup>

**In Vivo Two-Stage Carcinogenesis Assay for Nitrocapsanthins on Mouse Skin Papillomas Initiated by DMBA and Promoted by TPA.** The animals (specific pathogen-free female ICR 6 week old mice) were divided into three experimental groups, each with 10 mice. The backs of the mice were shaved with surgical clippers, and they were treated topically with DMBA (100  $\mu$ g, 390 nmol) in acetone (0.1 mL) as the initiator. One week after initiation, papilloma formation was promoted twice a week by the application of TPA (1  $\mu$ g, 1.7 nmol) in acetone (0.1 mL) to the skin. Group 1 (control group)



**Figure 2.** (A) HPLC of products of reaction of capsanthin with peroxynitrite. Peaks: 1, capsanthin; 3, (14'Z)-15'-nitrocapsanthin; and 4, 12-nitrocapsanthin. (B) HPLC of products of reaction of fucoxanthin with peroxynitrite. Peaks: 2, fucoxanthin; 5, (14Z)-15-nitrofucoxanthin; 6, (11Z)-11-nitrofucoxanthin; and 7, (14Z,9Z)-15-nitrofucoxanthin.

received TPA treatment alone, and groups II and III received the topical application of 12-nitrocapsanthin (4) (85 nmol) and (14'Z)-15'-nitrocapsanthin (3) (85 nmol) in acetone, respectively, 1 h before the TPA treatment. The incidence and numbers of papillomas were monitored weekly for 20 weeks.

Experiments involving mice were conducted in accordance with Kanazawa University, Institute for Experimental Animals and use Committee Guidelines under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology.

## RESULTS AND DISCUSSION

**Structure of Products of Capsanthin and Fucoxanthin Reaction with Peroxynitrite.** Capsanthin (1) was reacted with peroxynitrite, and the reaction products were analyzed by HPLC, as shown in Figure 2A. Two major reaction products, compounds 3 and 4, were obtained.

Compound 3 showed absorption maxima at 359 and 456 nm. Its molecular formula was determined as C<sub>40</sub>H<sub>55</sub>O<sub>5</sub>N by HRFAB-MS, and it demonstrated a NO<sub>2</sub>-substituted capsanthin structure. This structure was also characterized from <sup>1</sup>H and <sup>13</sup>C NMR including 2D NMR experiments. The partial structure of the end group and the polyene chain of compound 3 were characterized by <sup>1</sup>H NMR and <sup>13</sup>C NMR including <sup>1</sup>H–<sup>1</sup>H correlation spectroscopy (COSY), nuclear Overhauser effect spectroscopy (NOESY), heteronuclear single quantum coherence (HSQC), and heteronuclear multiple bond correlation (HMBC) experiments. The downfield shift of the <sup>13</sup>C NMR

signal at C-15' ( $\delta$  145.1, quaternary carbon) along with disappearance of a methine proton at the C-15' position in  $^1\text{H}$  NMR as compared with capsanthin clearly indicated that a nitro group was attached to the C-15 position of capsanthin. Furthermore, the change in the coupling pattern and the downfield shifts of the  $^1\text{H}$  NMR signals at H-15 ( $\delta$  8.09) and H-14' ( $\delta$  6.41) as compared with capsanthin supported the substitution position of the nitro group at C-15'. The steric structure was confirmed by NOESY correlations between  $\text{CH}_3$ -16/17 and H-7,  $\text{CH}_3$ -19 and H-7/11,  $\text{CH}_3$ -20 and H-11/15,  $\text{CH}_3$ -19' and H-7'/11', and  $\text{CH}_3$ -20' and H-11'/14. Therefore, the structure of **3** was determined to be (14'Z)-15'-nitrocapsanthin (**3**), as shown in Figure 1. A high intensity *cis* peak in the UV/vis spectrum (about 80%  $A_{\text{B}}/A_{\text{II}}$ ) of **3** was also in agreement with this structure.<sup>20</sup>

Compound **4** showed absorption maxima at 346 and 456 nm. Its molecular formula was also determined to be  $\text{C}_{40}\text{H}_{55}\text{O}_5\text{N}$  by HRFAB-MS, compatible with the formula of nitrocapsanthin. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR signals of **4** were assigned based on  $^1\text{H}$ - $^1\text{H}$  COSY, NOESY, HSQC, and HMBC experiments. The appearance of a quaternary carbon at  $\delta$  152.4 (C-12) in the  $^{13}\text{C}$  NMR spectrum, along with the disappearance of a methine proton at the C-12 position in  $^1\text{H}$  NMR as compared with capsanthin clearly indicated that a nitro group was attached to the C-12 position of capsanthin. Furthermore, the change in the coupling pattern from double doublet to doublet and the downfield shifts of the  $^1\text{H}$  NMR signals at H-11 ( $\delta$  7.99) as compared with capsanthin also supported the substitution position of the nitro group at C-12. The *trans* geometry of the polyene chain in (**4**) was determined based on NOESY data, as shown in Figure 1. Disappearance of the *cis* peak in UV/vis spectrum also supports this geometry.<sup>20</sup> Therefore, the structure of **4** was determined to be 12-nitrocapsanthin (Figure 1). Employing a similar method to that described above, fucoxanthin (**2**) was reacted with peroxy-nitrite, and the reaction products were analyzed by HPLC, as shown in Figure 2B.

Compound **5** showed absorption maxima at 314 and 451 nm. Its molecular formula was determined to be  $\text{C}_{42}\text{H}_{57}\text{O}_8\text{N}$  by HRFAB-MS, and it demonstrated an  $\text{NO}_2$ -substituted fucoxanthin structure. This structure was also characterized from  $^1\text{H}$  and  $^{13}\text{C}$  NMR including 2D NMR experiments. The partial structure of the end group and the polyene chain of compound **5** was characterized by  $^1\text{H}$  NMR including  $^1\text{H}$ - $^1\text{H}$  COSY and NOESY experiments. The disappearance of a methine proton at the C-15 position and in  $^1\text{H}$  NMR and the change in the coupling pattern from double doublet to doublet at H-15' as compared with fucoxanthin clearly indicated that a nitro group was attached to the C-15 position of fucoxanthin. The marked downfield shift of quaternary carbon at C-15 ( $\delta$  150.3) was in agreement with this structure. The steric structure was confirmed by NOESY correlations between H-7 and H-11,  $\text{CH}_3$ -19 and H-11,  $\text{CH}_3$ -20 and H-11,  $\text{CH}_3$ -19' and H-11', and  $\text{CH}_3$ -20' and H-11'/15', as shown in Figure 1. Therefore, the structure of **5** was determined to be (14Z)-15-nitrofucoxanthin (**5**). A high-intensity *cis* peak in the UV/vis spectrum (about 80%  $A_{\text{B}}/A_{\text{II}}$ ) of **5** was also in agreement with this structure.<sup>20</sup>

Compound **6** showed absorption maxima at 334 and 456 nm. Its molecular formula was determined to be  $\text{C}_{42}\text{H}_{57}\text{O}_8\text{N}$  by HRFAB-MS, and it demonstrated an  $\text{NO}_2$ -substituted fucoxanthin structure. This structure was also characterized from  $^1\text{H}$  and  $^{13}\text{C}$  NMR including 2D NMR experiments. The disappearance of a methine proton at the C-11 position and in  $^1\text{H}$  NMR and the change in the coupling pattern from double to singlet at

H-10 ( $\delta$  7.31) and H-12 ( $\delta$  7.91) as compared with fucoxanthin clearly indicated that a nitro group was attached to the C-11 position of fucoxanthin. The marked downfield shift of quaternary carbon at C-11 ( $\delta$  141.6) was in agreement with this structure. NOESY correlations between  $\text{CH}_3$ -20 and H-10 and between H-7 and H-10 indicated the (11Z) configuration. Therefore, the structure of **6** was determined to be 11-*cis*-11-nitrofucoxanthin (**6**), as shown in Figure 1.

Compound **7** also showed a molecular formula of  $\text{C}_{42}\text{H}_{57}\text{O}_8\text{N}$  by HRFAB-MS.  $^1\text{H}$  NMR was similar to that of (14Z)-15-nitrofucoxanthin (**3**) except for H-7', H-10', and H-11'. The marked downfield shift of H-7' (0.54 ppm) as compared with that of **5** suggested that this compound was a 9'-*cis* isomer of **3**. NOESY correlations between H-19' and H-10' and between H-7' and H-11' were in agreement with this structure. Therefore, **7** was determined to be (14Z,9'Z)-15-nitrofucoxanthin (Figure 1).

Other minor reaction products were obtained. Because of the small amount of samples, complete structural characterization could not be accomplished. From the partial assignment of  $^1\text{H}$  NMR, they may be 12- and 12'-nitrofucoxanthins.

**Inhibition of Nitration of Tyrosine with Peroxynitrite by Carotenoids.** Capsanthin inhibited the nitration of tyrosine by peroxy-nitrite. Capsanthin suppressed the formation of nitrotyrosine to about 10.5% of that of the control group. This effect was almost the same as that of  $\gamma$ -tocopherol (9.2%). A similar result was also obtained in the case of fucoxanthin (11.5%). These results indicate that capsanthin and fucoxanthin are able to capture peroxy-nitrite to form nitrocarotenoids and inhibit the nitration of tyrosine.

It was reported that phenolic compounds such as *p*-coumaric acid and pelargonidin could scavenge peroxy-nitrite by the formation of nitro-*p*-coumaric acid and nitro-pelargonidin, respectively, and protect against the nitration of tyrosine.<sup>21–23</sup> Similar results were reported for tocopherols.<sup>24,25</sup> Our investigations also indicated that carotenoids could take up peroxy-nitrite through the formation of nitrocarotenoids.

**Antitumor-Promoting Activity of Nitrocapsanthins and Nitrofucoxanthin.** It is well-known that peroxy-nitrite and nitric oxide are strong initiators of carcinogenesis.<sup>26,27</sup> Previously, we reported that paprika carotenoids such as capsanthin inhibited the carcinogenesis initiated by peroxy-nitrite and promoted with TPA using a two-stages mouse carcinogenesis model.<sup>12</sup> This result suggested that capsanthin inhibited peroxy-nitrite-initiated carcinogenesis by the uptake of peroxy-nitrite and nitrocarotenoids themselves and that this might have an anticarcinogenic effect.

Thus, antitumor-promoting activities of nitrocapsanthins and nitrofucoxanthin were investigated. The *in vitro* antitumor-promoting activity of nitrocapsanthins (**3** and **4**) and nitrofucoxanthins (**5** and **6**) was examined using the Epstein–Barr virus (EBV) activation assay in Raji cells. The results are shown in Table 2. Nitrocapsanthins (**3** and **4**) and nitrofucoxanthins (**5** and **6**) showed inhibitory effects on the EBV-EA induction of Raji cells without significant cytotoxicity (more than 60% viability of Raji cells) in this assay. Among them, nitrofucoxanthins (**5** and **6**) showed slightly higher activity than fucoxanthin (**2**). Furthermore, nitrocapsanthins (**3** and **4**) and nitrofucoxanthins (**5** and **6**) inhibited the proliferation of human pancreatic cancer cells, as shown in Table 3. These results showed that nitrocarotenoids themselves have anticarcinogenic activity.

**Table 2.** Relative Rate of EBV-EA Activation<sup>a</sup> with Respect to the Positive Control (100%) in the Presence of Carotenoids (1–6)

concn (mol ratio/TPA) <sup>b</sup>	1000	500	100	10	IC <sub>50</sub>
compds	values				
capsanthin (1)	5.5 (>60) <sup>c</sup>	29.4	78.1	100	310
12-nitrocapsanthin (4)	7.4 (>60)	30.9	79.7	100	346
(14'Z)-15'-nitrocapsanthin (3)	4.6 (>60)	26.9	76.8	100	305
fucoxanthin (2)	3.1 (>60)	26.8	76.6	100	296
(11Z)-11-nitrofucoxanthin (6)	1.3 (>60)	23.6	72.0	95.0	275
(14Z)-15-nitrofucoxanthin (5)	2.6 (>60)	25.0	74.2	100	282


<sup>a</sup> Values represent the percentage relative to the positive control values (100%). <sup>b</sup> TPA concentration was 20 ng (32 pmol)/mol. <sup>c</sup> Values in parentheses are percentage viability of Raji cells. There are significant differences ( $P < 0.01$ ) in inhibitory capacity in treatment groups of compounds 1–5 as compared with the control group.

**Table 3.** Relative Ratio of Antiproliferative Effects on Human Pancreatic Carcinoma (MIA PaVa-2) with Respect to the Positive Control (100%) in the Presence of Carotenoids (1–6)<sup>a</sup>

concn	% to control group	
	1 mM	0.1 mM
compds	values	
capsanthin (1)	90	100
12-nitrocapsanthin (4)	90	100
(14'Z)-15'-nitrocapsanthin (3)	80	100
fucoxanthin (2)	70	90
(11Z)-11-nitrofucoxanthin (6)	60	90
(14Z)-15-nitrofucoxanthin (5)	80	100

<sup>a</sup> There are significant differences ( $P < 0.01$ ) in inhibitory capacity in the treatment groups of compounds 1–6 at 1 mM as compared with the control group.

Furthermore, the inhibitory effects of nitrocapsanthins on two-stages mouse skin carcinogenesis were investigated. The incidence (%) of papilloma-bearing mice and the average number of papillomas per mouse are presented and compared with a control group in Figure 3. When 12-nitrocapsanthin (4) (85 nmol) and (14'Z)-15'-nitrocapsanthin (3) (85 nmol) were applied before each TPA treatment, they markedly delayed the formation of papillomas and reduced the number per mouse, as shown in Figure 3. In the positive control group, the first papillomas appeared within 5 weeks of promotion, and in groups treated with 12-nitrocapsanthin (4) and (14'Z)-15'-nitrocapsanthin (3), the first papillomas appeared at 6 and 8 weeks, respectively. After 11 weeks of promotion, the control group showed a 100% incidence of papillomas, while in groups treated with 12-nitrocapsanthin (4) and (14'Z)-15'-nitrocapsanthin (3), only 50 and 30% of mice bore papillomas, respectively. After 20 weeks of promotion, 7.9 papillomas were found per mouse in the control group, whereas only 5.9 and 4.1 papillomas were found per mouse in the groups treated with 12-nitrocapsanthin (4) (85 nmol) and (14'Z)-15'-nitrocapsanthin (3), respectively. These results indicate that nitrocapsanthins (3 and 4) also had



**Figure 3.** Inhibitory effects of casanthin on DMBA-induced mouse skin carcinogenesis. (A) Percentage of mice bearing papillomas and (B) average numbers of papillomas per mouse. Group I, DMBA (390 nmol) + TPA (1.7 nmol) (●). Group II, 12-nitrocapsanthin (4) (85 nmol) + peroxynitrite (390 nmol) + TPA (1.7 nmol) (■). Group III, (14'Z)-15'-nitrocapsanthin (3) (85 nmol) + peroxynitrite (390 nmol) + TPA (1.7 nmol) (▲).

inhibitory effects on two stages of mouse skin carcinogenesis as well as capsanthin.<sup>11</sup>

In conclusion, capsanthin and fucoxanthin could take up peroxynitrite through the formation of nitrocapsanthins and nitrofucoxanthins, respectively, and inhibit the nitration of tyrosine by peroxynitrite. Furthermore, nitrocapsanthins and nitrofucoxanthins exhibited antitumor-promoting activity. Therefore, carotenoids such as capsanthin and fucoxanthin may have the potential to reduce the risk of disease induced by reactive nitrogen species. Paprika and sea weeds, which contain capsanthin (1) and fucoxanthin (2) as major carotenoids,

respectively, might be valuable foods as prevention for active nitrogen-induced disease.

## AUTHOR INFORMATION

### Corresponding Author

\*Tel: +81-75-781-1107. Fax: +81-75-791-7659. E-mail: maoka@mbx.kyoto-inet.or.jp.

### Funding Sources

This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (Grant No. 20580126).

## REFERENCES

- (1) Maoka, T.; Hideo Etoh, H. Some biological functions of carotenoids in Japanese food. In *Functional Foods of the East*; Shi, J., Ho, C.-T., Shahidi, F., Eds.; CRC Press: Boca Raton, 2010; pp 85–97.
- (2) Scheidegger, R.; Pande, A. K.; Bounds, P. L.; Koppenol, W. H. The reaction of peroxynitrite with zeaxanthin. *Nitric Oxide: Biol. Chem.* **1998**, *2*, 8–16.
- (3) Kikugawa, K.; Hiramoto, K.; Tomiyama, S.; Asano, Y.  $\beta$ -Carotene effectively scavenges toxic nitrogen oxides: Nitrogen dioxide and peroxynitrous acid. *FEBS Lett.* **1997**, *404*, 175–178.
- (4) Yoshioka, R.; Hayakawa, T.; Ishizuka, K.; Kulkarni, A.; Terada, Y.; Maoka, T.; Etoh, H. Nitration reaction of astaxanthin and  $\beta$ -carotene by peroxynitrite. *Tetrahedron Lett.* **2006**, *47*, 3637–3640.
- (5) Hayakawa, T.; Kulkarni, A.; Terada, Y.; Maoka, T.; Etoh, H. Reaction of astaxanthin with peroxynitrite. *Biosci., Biotechnol., Biochem.* **2008**, *72*, 2716–2722.
- (6) Tsuboi, M.; Etoh, H.; Yomoda, Y.; Kato, K.; Kato, H.; Kulkarni, A.; Terada, Y.; Maoka, T.; Mori, H.; Inakuma, T. Nitration reaction of lutein with peroxynitrite. *Tetrahedron Lett.* **2010**, *51*, 676–678.
- (7) Hirayama, O.; Nakamura, K.; Hamada, S.; Kobayashi, K. Singlet oxygen quenching ability of naturally occurring carotenoids. *Lipids* **1994**, *29*, 149–150.
- (8) Matsufuji, H.; Nakamura, H.; Chino, M.; Takeda, M. Antioxidant activity of capsanthin and fatty acid esters in paprika (*Capsicum annuum*). *J. Agric. Food Chem.* **1998**, *46*, 3468–3472.
- (9) Maoka, T.; Goto, Y.; Isobe, K.; Fujiwara, Y.; Hashimoto, K.; Mochida, K. Antioxidative activity of capsorubin and related compounds from paprika (*Capsicum annuum*). *J. Oleo Sci.* **2001**, *50*, 663–665.
- (10) Murakami, A.; Nakashima, M.; Koshihara, T.; Maoka, T.; Nishino, H.; Yano, M.; Sumida, T.; Kim, O.; Koshimizu, K.; Ohigashi, H. Modifying effects of carotenoids on superoxide and nitric oxide generation from stimulated leukocyte. *Cancer Lett.* **2000**, *149*, 115–123.
- (11) Maoka, T.; Mochida, K.; Kozuka, M.; Ito, Y.; Fujiwara, Y.; Hashimoto, K.; Enjo, F.; Ogata, M.; Nobukuni, Y.; Tokuda, H.; Nishino, H. Cancer chemopreventive activity of carotenoids in the fruits of red paprika *Capsicum annuum* L. *Cancer Lett.* **2001**, *172*, 103–109.
- (12) Maoka, T.; Mochida, K.; Kozuka, M.; Enjo, F.; Kuchide, M.; Nobukuni, Y.; Tokuda, H.; Nishino, H. Chemopreventive activity of paprika extract and capsanthin on nitric oxide or peroxynitrite induced carcinogenesis (in Japanese). *Syokuhin Rinsyo Eiyo* **2006**, *1*, 7–14.
- (13) Sachindra, N. M.; Sato, E.; Maeda, H.; Hosokawa, M.; Niwano, Y.; Kohno, M.; Miyashita, K. Radical Scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. *J. Agric. Food Chem.* **2008**, *56*, 8516–8522.
- (14) Das, S. K.; Hashimoto, T.; Shimizu, K.; Yoshida, T.; Sakai, T.; Sowa, Y.; Komoto, A.; Kanazawa, K. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. *Biochim. Biophys. Acta* **2005**, *1726*, 328–335.
- (15) Satomi, Y.; Nishino, H. Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human, cancer cells. *In Vivo* **2007**, *21*, 305–309.
- (16) Maeda, H.; Hosokawa, M.; Sashima, T.; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. *J. Agric. Food Chem.* **2007**, *55*, 7701–7706.
- (17) Maeda, H.; Hosokawa, M.; Sashima, T.; Funayama, K.; Miyashita, K. Fucoxanthin from edible seaweed, *Undaria pinnatifida*, shows antiobesity effect through UPC1 expression in white adipose tissues. *Biochem. Biophys. Res. Commun.* **2005**, *332*, 392–397.
- (18) Tsushima, M.; Maoka, T.; Katsuyama, M.; Kozuka, M.; Matsuno, T.; Tokuda, H.; Nishino, H.; Iwashima, A. Inhibitory effect of natural carotenoids on Epstein-Barr virus activation activity of a tumor promoter in Raji cells. A screening study for anti-tumor promoters. *Biol. Pharm. Bull.* **1995**, *18*, 227–233.
- (19) Yunis, A. A.; Arimura, G. K.; Russin, D. J. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitivity to asparaginase. *Int. J. Cancer* **1997**, *19*, 128–135.
- (20) Britton, G. UV/Visible Spectroscopy. In *Carotenoids*; Britton, G., Liaaen-Jensen, S., Pfander, H., Eds.; Birkhäuser Verlag: Basel, 1995; Vol. 1B, pp 13–62.
- (21) Niwa, T.; Doi, U.; Kato, Y.; Osawa, T. Antioxidative properties of phenolic antioxidants isolated from corn steep liquor. *J. Agric. Food Chem.* **2001**, *49*, 177–182.
- (22) Kato, Y.; Ogino, Y.; Aoki, T.; Uchida, K.; Kawakishi, S.; Osawa, T. Phenolic antioxidants prevent peroxynitrite-derived collagen modification in vitro. *J. Agric. Food Chem.* **1997**, *45*, 3004–3009.
- (23) Tsuda, T.; Kato, Y.; Osawa, T. Mechanism for the peroxynitrite scavenging activity by anthocyanins. *FEBS Lett.* **2000**, *484*, 207–210.
- (24) P., A.; Goaa, S. P. A.; Hogg, N.; Kalyanaraman, B. The effect of  $\alpha$ -tocopherol on the nitration of  $\gamma$ -tocopherol by peroxynitrite. *Arch. Biochem. Biophys.* **1999**, *363*, 333–340.
- (25) Morton, L. W.; Ward, N. C.; Croft, K. D.; Puddey, I. B. Evidence for the nitration of  $\gamma$ -tocopherol in vivo: 5-Nitro- $\gamma$ -tocopherol is elevated in the plasma of subjects with coronary heart disease. *Biochem. J.* **2002**, *364*, 625–628.
- (26) Halliwell, B. Free radicals, antioxidants, and human disease: Curiosity, cause or consequence? *Lancet* **1994**, *344*, 721–724.
- (27) Wink, D. A.; Kasprak, K. S.; Maragos, C. M.; Elespuru, R. K.; Misra, M.; Dunams, T. M.; Cebula, T. A.; Koch, W. H.; Andrews, A. W.; Allen, J. S.; Keffer, L. K. DNA deaminating activity and genotoxicity of nitric oxide and its progenitors. *Science* **1991**, *254*, 1001–1003.